BioRender
PrivateLast Round
VC Round
Dec 18, 2025
Est. Valuation
$900M
Total Funding Raised
$45.12M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
BioRender operates in Healthcare & Life Sciences and is based in Toronto, Ontario. Its latest recorded funding round was a VC Round in December 2025.
BioRender is a software company that provides a science illustration software designed to empower the world to learn and communicate science through visuals.
Sector
Healthcare & Life Sciences
Verticals
Vertical SaaS, Content Creation, Biotechnology
Business Model
B2B
Customer Profile
Subscription SaaS, Freemium
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioRender Comparables
Compare BioRender with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cactus Communications | 82% | |
| SciFig | 71% | |
| Illustrae | 71% |
For institutional investors. Book with your work email.
BioRender Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 18, 2025 | ||||
| Series B | Mar 21, 2022 | ||||
| Accelerator | Mar 21, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioRender Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Refactor Capital | Accelerator |
| TCV | Series B |
| Inovia Capital | Series B |
| Dimension | VC Round |
| Real Ventures | Series B |
| Y Combinator | Series B, Accelerator |
| Dimension | VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 25, 2026
Job posting discloses that its figures have appeared in more than 54,000 publications.
- Jun 25, 2026
Announced the launch of BioRender Graphing.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 6, 2026
BioRender launches Leo by BioRender, an AI agent built specifically for scientific figures that helps researchers create accurate, clear, and editable images, in Canada on Oct 6th '26.
- has_revenueSep 2, 2026
BioRender reports $36.5M in revenue for 2024.
- has_revenueSep 2, 2026
BioRender has estimated revenue of $30.8M in Jun '24.
For institutional investors. Book with your work email.
BioRender Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioRender's valuation, stock price, and market status.
Is BioRender a public or private company?
BioRender is a private company.
What is the current stock price of BioRender?
BioRender is a private company, so its shares have no public market price. Caplight tracks BioRender's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioRender worth (valuation)?
BioRender's valuation is estimated at $900.0M based on funding round data.
Can I buy BioRender stock?
BioRender shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioRender's last funding round?
BioRender's most recent funding round was VC Round on December 18, 2025.
Who are the main investors in BioRender?
Key investors in BioRender include TCV, Inovia Capital, Dimension, Y Combinator, Dimension.
Will BioRender IPO soon?
No public IPO plans have been announced for BioRender.
How can I track BioRender secondary market activity?
Caplight tracks bids, offers, and trades in BioRender's shares on secondary markets.